search
Back to results

Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)

Primary Purpose

Chronic Obstructive Pulmonary Disease, Lung Disease

Status
Completed
Phase
Phase 2
Locations
Germany
Study Type
Interventional
Intervention
AZD2423
AZD2423 Placebo
Sponsored by
AstraZeneca
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Chronic Obstructive Pulmonary Disease focused on measuring Respiratory disease, chronic obstructive pulmonary disease

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Only women of non-child bearing potential are included in the study i.e. women who are permanently or surgically sterilised or post menopausal.
  • ≥ 40 years of age at Visit 1
  • Clinical diagnosis of COPD (GOLD stage 1)
  • FEV1 ≥ 80% of the predicted normal post-bronchodilator at Visit 1 (GOLD stage 1)
  • FEV1/FVC <70% post-bronchodilator at Visit 1 (GOLD stage 1)

Exclusion Criteria:

  • Any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk or influence the way the drug works
  • Any clinically relevant abnormal findings in physical examination, blood or urine test results, vital signs or ECG at Visit 1 that may put the subject at risk during the study, affect their ability or take part or influence the results of the study
  • A past history or current indication of renal (kidney) failure
  • Subjects at risk of active tuberculosis or of disease reactivation
  • Subjects who have had any clinically significant illness within 4 weeks before Visit 2 (start of treatment)

Sites / Locations

  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

1

2

Arm Description

Oral treatment

Oral treatment

Outcomes

Primary Outcome Measures

Absolute Monocyte Count in BAL Post-LPS Challenge
Monocyte count in BAL post-LPS challenge (Day 11)

Secondary Outcome Measures

Total Neutrophils in Biopsy Sample (Post-LPS Challenge)
Pre-challenge = Day 11. Biopsies taken from left lingula. Cells counted in subepithelium.
Total Macrophages in Biopsy Sample (Post-LPS Challenge)
Post-LPS challenge data (Day 11). Post-LPS challenge biopsies taken from right middle lobe. Cells counted in subepithelium.
CD45+ in Biopsy Sample (Post-LPS Challenge)
Post-LPS challenge data (Day 11). Post-LPS challenge biopsies taken from right middle lobe. Cells counted in subepithelium.
CD3+ in Biopsy Sample (Post-LPS Challenge)
Post-LPS challenge data (Day 11). Post-LPS challenge biopsies taken from right middle lobe. Cells counted in subepithelium.
Biopsy PAS Reaction Grade (Post-LPS Challenge)
Biopsies stained using PAS method. Graded on subjective scale (1=normal; 2=PAS positive cell hypertrophy; 3=PAS positive cell hyperplasia; 4=Metaplasia with PAS positive cells throughout mucosa; 5=Metaplasia and/or squamous plates with loss of PAS positive cells).
Biopsy Epithelium Grade (Post-LPS Challenge)
Biopsies (from right middle lobe) were assessed for routine histopathology. Epithelial morphology was graded on subjective scale from 1 to 5. 1=normal; 2=PAS positive cell hypertrophy; 3=PAS positive cell hyperplasia; 4=Metaplasia with PAS positive cells throughout mucosa; 5=Metaplasia and/or squamous plates with loss of PAS positive cells
Eosinophils in BAL (Post-LPS Challenge)
Post-LPS challenge eosinophil differential in BAL. LPS challenge and post-challenge BAL conducted at right middle lobe.
Lymphocytes in BAL (Post-LPS Challenge)
Post-LPS challenge lymphocyte differential in BAL. LPS challenge and post-challenge BAL conducted at right middle lobe.
Neutrophils in BAL (Post-LPS Challenge)
Post-LPS challenge neutrophil differential in BAL. LPS challenge and post-challenge BAL conducted at right middle lobe.
Macrophages in BAL (Post-LPS Challenge)
Post-LPS challenge macrophage differential in BAL. LPS challenge and post-challenge BAL conducted at right middle lobe.
TNF α Concentration in BAL (Post-LPS Challenge)
Post-LPS challenge TNF α concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.
CCL2 Concentration in BAL (Post-LPS Challenge)
Post-LPS challenge CCL2 concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.
IL-1β Concentration in BAL (Post-LPS Challenge)
Post-LPS challenge IL-1β concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.
IL-6 Concentration in BAL (Post-LPS Challenge)
Post-LPS challenge IL-6 concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.
IL-8 Concentration in BAL (Post-LPS Challenge)
Post-LPS challenge IL 8 concentration in BAL. LPS challenge and post-LPS challenge BAL conducted at right middle lobe.
RANTES Concentration in BAL (Post-LPS Challenge)
Post-LPS challenge RANTES concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.
SP-D Concentration in BAL (Post-LPS Challenge)
Post-LPS challenge SP-D concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.
SAA Concentration in Blood (Pre-LPS Challenge)
SAA concentration in blood pre-LPS challenge (Day 10).
SAA Concentration in Blood (Post-LPS Challenge)
SAA concentration in blood post-LPS challenge (Day 11)
CCL2 Concentration in Blood (Pre-LPS Challenge)
CCL2 concentration in blood pre-LPS challenge (Day 10)
CCL2 Concentration in Blood (Post-LPS Challenge)
CCL2 concentration in blood post-LPS challenge (Day 11).
IL-1β Concentration in Blood (Pre-LPS Challenge)
IL-1β concentration in blood pre-LPS challenge (Day 10)
IL-1β Concentration in Blood (Post-LPS Challenge)
IL-1β concentration in blood post-LPS challenge (Day 11)
IL-6 Concentration in Blood (Pre-LPS Challenge)
IL-6 concentration in blood pre-LPS challenge (Day 10)
IL-6 Concentration in Blood (Post-LPS Challenge)
IL-6 concentration in blood post-LPS challenge (Day 11)
IL-8 Concentration in Blood (Pre-LPS Challenge)
IL-8 concentration in blood pre-LPS challenge (Day 10)
IL-8 Concentration in Blood (Post-LPS Challenge)
IL-8 concentration in blood post-LPS challenge (Day 11)
TNF-α Concentration in Blood (Pre-LPS Challenge)
TNF-α concentration in blood pre-LPS challenge (Day 10)
TNF-α Concentration in Blood (Post-LPS Challenge)
TNF-α concentration in blood post-LPS challenge (Day 11)
SP-D Concentration in Blood (Pre-LPS Challenge)
SP-D concentration in blood pre-LPS challenge (Day 10)
SP-D Concentration in Blood (Post-LPS Challenge)
SP-D concentration in blood post-LPS challenge (Day 11)
CC16 Concentration in Blood (Pre-LPS Challenge)
CC16 concentration in blood pre-LPS challenge (Day 10)
CC16 Concentration in Blood (Post-LPS Challenge)
CC16 concentration in blood post-LPS challenge (Day 11)
Basophils in Blood (Pre-LPS Challenge)
Basophils in blood pre-LPS challenge (Day 10)
Basophils in Blood (Post-LPS Challenge)
Basophils in blood post-LPS challenge (Day 11)
Eosinophils in Blood (Pre-LPS Challenge)
Eosinophils in blood pre-LPS challenge (Day 10)
Eosinophils in Blood (Post-LPS Challenge)
Eosinophils in blood post-LPS challenge (Day 11)
Lymphocytes in Blood (Pre-LPS Challenge)
Lymphocytes in blood pre-LPS challenge (Day 10)
Lymphocytes in Blood (Post-LPS Challenge)
Lymphocytes in blood post-LPS challenge (Day 11)
Monocytes in Blood (Pre-LPS Challenge)
Monocytes in blood pre-LPS challenge (Day 10)
Monocytes in Blood (Post-LPS Challenge)
Monocytes in blood post-LPS challenge (Day 11)
Neutrophils in Blood (Pre-LPS Challenge)
Neutrophils in blood pre-LPS challenge (Day 10)
Neutrophils in Blood (Post-LPS Challenge)
Neutrophils in blood post-LPS challenge (Day 11)
Maximum Plasma Concentration (Cmax) of AZD2423 at Steady State
Steady state pharmacokinetic (PK) profile measured on Day 10
Time to Cmax (Tmax) of AZD2423 at Steady State
Steady state PK profile measured on Day 10
Area Under the Plasma Concentration-time Curve From Zero to 24 Hours (AUC(0-24)) of AZD2423 at Steady State
Steady state PK profile measured on Day 10
Area Under the Plasma Concentration-time Curve From Zero to 8 Hours (AUC(0-8)) of AZD2423 at Steady State
Steady state PK profile measured on Day 10
Number of Participants With Clinically Relevant Treatment-related Changes in Laboratory Variables Other Than Monocytes
Number of Participants With Clinically Relevant Changes in Vital Signs
Number of Participants With Clinically Relevant Changes in Electrocardiogram (ECG) Variables
Number of Participants With Clinically Relevant Changes in Physical Examination
Number of Participants With Treatment-related or Clinically Relevant Changes in Spirometry (Forced Expiratory Volume in 1 Second [FEV1], Forced Vital Capacity [FVC] Pre-bronchodilator)
CC16 Concentration in BAL (Post-LPS Challenge)
Post-LPS challenge CC16 concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.

Full Information

First Posted
June 28, 2010
Last Updated
March 23, 2015
Sponsor
AstraZeneca
search

1. Study Identification

Unique Protocol Identification Number
NCT01153321
Brief Title
Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)
Official Title
A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase IIa Study to Investigate the Effects of 100mg AZD2423 as an Oral Tablet in Subjects With Mild COPD Following Segmental Endobronchial LPS Instillation
Study Type
Interventional

2. Study Status

Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
October 2010 (undefined)
Primary Completion Date
July 2011 (Actual)
Study Completion Date
July 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to find out if AZD2423 can reduce inflammation in the lungs of patients with mild COPD.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Obstructive Pulmonary Disease, Lung Disease
Keywords
Respiratory disease, chronic obstructive pulmonary disease

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
71 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Oral treatment
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
Oral treatment
Intervention Type
Drug
Intervention Name(s)
AZD2423
Intervention Description
100mg Oral dose od
Intervention Type
Drug
Intervention Name(s)
AZD2423 Placebo
Intervention Description
Oral dose od
Primary Outcome Measure Information:
Title
Absolute Monocyte Count in BAL Post-LPS Challenge
Description
Monocyte count in BAL post-LPS challenge (Day 11)
Time Frame
Day 11
Secondary Outcome Measure Information:
Title
Total Neutrophils in Biopsy Sample (Post-LPS Challenge)
Description
Pre-challenge = Day 11. Biopsies taken from left lingula. Cells counted in subepithelium.
Time Frame
Day 11
Title
Total Macrophages in Biopsy Sample (Post-LPS Challenge)
Description
Post-LPS challenge data (Day 11). Post-LPS challenge biopsies taken from right middle lobe. Cells counted in subepithelium.
Time Frame
Day 11
Title
CD45+ in Biopsy Sample (Post-LPS Challenge)
Description
Post-LPS challenge data (Day 11). Post-LPS challenge biopsies taken from right middle lobe. Cells counted in subepithelium.
Time Frame
Day 11
Title
CD3+ in Biopsy Sample (Post-LPS Challenge)
Description
Post-LPS challenge data (Day 11). Post-LPS challenge biopsies taken from right middle lobe. Cells counted in subepithelium.
Time Frame
Day 11
Title
Biopsy PAS Reaction Grade (Post-LPS Challenge)
Description
Biopsies stained using PAS method. Graded on subjective scale (1=normal; 2=PAS positive cell hypertrophy; 3=PAS positive cell hyperplasia; 4=Metaplasia with PAS positive cells throughout mucosa; 5=Metaplasia and/or squamous plates with loss of PAS positive cells).
Time Frame
Day 11
Title
Biopsy Epithelium Grade (Post-LPS Challenge)
Description
Biopsies (from right middle lobe) were assessed for routine histopathology. Epithelial morphology was graded on subjective scale from 1 to 5. 1=normal; 2=PAS positive cell hypertrophy; 3=PAS positive cell hyperplasia; 4=Metaplasia with PAS positive cells throughout mucosa; 5=Metaplasia and/or squamous plates with loss of PAS positive cells
Time Frame
Day 11
Title
Eosinophils in BAL (Post-LPS Challenge)
Description
Post-LPS challenge eosinophil differential in BAL. LPS challenge and post-challenge BAL conducted at right middle lobe.
Time Frame
Day 11
Title
Lymphocytes in BAL (Post-LPS Challenge)
Description
Post-LPS challenge lymphocyte differential in BAL. LPS challenge and post-challenge BAL conducted at right middle lobe.
Time Frame
Day 11
Title
Neutrophils in BAL (Post-LPS Challenge)
Description
Post-LPS challenge neutrophil differential in BAL. LPS challenge and post-challenge BAL conducted at right middle lobe.
Time Frame
Day 11
Title
Macrophages in BAL (Post-LPS Challenge)
Description
Post-LPS challenge macrophage differential in BAL. LPS challenge and post-challenge BAL conducted at right middle lobe.
Time Frame
Day 11
Title
TNF α Concentration in BAL (Post-LPS Challenge)
Description
Post-LPS challenge TNF α concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.
Time Frame
Day 11
Title
CCL2 Concentration in BAL (Post-LPS Challenge)
Description
Post-LPS challenge CCL2 concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.
Time Frame
Day 11
Title
IL-1β Concentration in BAL (Post-LPS Challenge)
Description
Post-LPS challenge IL-1β concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.
Time Frame
Day 11
Title
IL-6 Concentration in BAL (Post-LPS Challenge)
Description
Post-LPS challenge IL-6 concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.
Time Frame
Day 11
Title
IL-8 Concentration in BAL (Post-LPS Challenge)
Description
Post-LPS challenge IL 8 concentration in BAL. LPS challenge and post-LPS challenge BAL conducted at right middle lobe.
Time Frame
Day 11
Title
RANTES Concentration in BAL (Post-LPS Challenge)
Description
Post-LPS challenge RANTES concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.
Time Frame
Day 11
Title
SP-D Concentration in BAL (Post-LPS Challenge)
Description
Post-LPS challenge SP-D concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.
Time Frame
Day 11
Title
SAA Concentration in Blood (Pre-LPS Challenge)
Description
SAA concentration in blood pre-LPS challenge (Day 10).
Time Frame
Day 10
Title
SAA Concentration in Blood (Post-LPS Challenge)
Description
SAA concentration in blood post-LPS challenge (Day 11)
Time Frame
Day 11
Title
CCL2 Concentration in Blood (Pre-LPS Challenge)
Description
CCL2 concentration in blood pre-LPS challenge (Day 10)
Time Frame
Day 10
Title
CCL2 Concentration in Blood (Post-LPS Challenge)
Description
CCL2 concentration in blood post-LPS challenge (Day 11).
Time Frame
Day 11
Title
IL-1β Concentration in Blood (Pre-LPS Challenge)
Description
IL-1β concentration in blood pre-LPS challenge (Day 10)
Time Frame
Day 10
Title
IL-1β Concentration in Blood (Post-LPS Challenge)
Description
IL-1β concentration in blood post-LPS challenge (Day 11)
Time Frame
Day 11
Title
IL-6 Concentration in Blood (Pre-LPS Challenge)
Description
IL-6 concentration in blood pre-LPS challenge (Day 10)
Time Frame
Day 10
Title
IL-6 Concentration in Blood (Post-LPS Challenge)
Description
IL-6 concentration in blood post-LPS challenge (Day 11)
Time Frame
Day 11
Title
IL-8 Concentration in Blood (Pre-LPS Challenge)
Description
IL-8 concentration in blood pre-LPS challenge (Day 10)
Time Frame
Day 10
Title
IL-8 Concentration in Blood (Post-LPS Challenge)
Description
IL-8 concentration in blood post-LPS challenge (Day 11)
Time Frame
day 11
Title
TNF-α Concentration in Blood (Pre-LPS Challenge)
Description
TNF-α concentration in blood pre-LPS challenge (Day 10)
Time Frame
Day 10
Title
TNF-α Concentration in Blood (Post-LPS Challenge)
Description
TNF-α concentration in blood post-LPS challenge (Day 11)
Time Frame
Day 11
Title
SP-D Concentration in Blood (Pre-LPS Challenge)
Description
SP-D concentration in blood pre-LPS challenge (Day 10)
Time Frame
Day 10
Title
SP-D Concentration in Blood (Post-LPS Challenge)
Description
SP-D concentration in blood post-LPS challenge (Day 11)
Time Frame
Day 11
Title
CC16 Concentration in Blood (Pre-LPS Challenge)
Description
CC16 concentration in blood pre-LPS challenge (Day 10)
Time Frame
Day 10
Title
CC16 Concentration in Blood (Post-LPS Challenge)
Description
CC16 concentration in blood post-LPS challenge (Day 11)
Time Frame
Day 11
Title
Basophils in Blood (Pre-LPS Challenge)
Description
Basophils in blood pre-LPS challenge (Day 10)
Time Frame
day 10
Title
Basophils in Blood (Post-LPS Challenge)
Description
Basophils in blood post-LPS challenge (Day 11)
Time Frame
Day 11
Title
Eosinophils in Blood (Pre-LPS Challenge)
Description
Eosinophils in blood pre-LPS challenge (Day 10)
Time Frame
Day 10
Title
Eosinophils in Blood (Post-LPS Challenge)
Description
Eosinophils in blood post-LPS challenge (Day 11)
Time Frame
Day 11
Title
Lymphocytes in Blood (Pre-LPS Challenge)
Description
Lymphocytes in blood pre-LPS challenge (Day 10)
Time Frame
Day 10
Title
Lymphocytes in Blood (Post-LPS Challenge)
Description
Lymphocytes in blood post-LPS challenge (Day 11)
Time Frame
Day 11
Title
Monocytes in Blood (Pre-LPS Challenge)
Description
Monocytes in blood pre-LPS challenge (Day 10)
Time Frame
Day 10
Title
Monocytes in Blood (Post-LPS Challenge)
Description
Monocytes in blood post-LPS challenge (Day 11)
Time Frame
Day 11
Title
Neutrophils in Blood (Pre-LPS Challenge)
Description
Neutrophils in blood pre-LPS challenge (Day 10)
Time Frame
Day 10
Title
Neutrophils in Blood (Post-LPS Challenge)
Description
Neutrophils in blood post-LPS challenge (Day 11)
Time Frame
Day 11
Title
Maximum Plasma Concentration (Cmax) of AZD2423 at Steady State
Description
Steady state pharmacokinetic (PK) profile measured on Day 10
Time Frame
Day 10 pre-dose, 20 and 40 minutes post-dose, 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose
Title
Time to Cmax (Tmax) of AZD2423 at Steady State
Description
Steady state PK profile measured on Day 10
Time Frame
Day 10 pre-dose, 20 and 40 minutes post-dose, 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose
Title
Area Under the Plasma Concentration-time Curve From Zero to 24 Hours (AUC(0-24)) of AZD2423 at Steady State
Description
Steady state PK profile measured on Day 10
Time Frame
Day 10 pre-dose, 20 and 40 minutes post-dose, 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose
Title
Area Under the Plasma Concentration-time Curve From Zero to 8 Hours (AUC(0-8)) of AZD2423 at Steady State
Description
Steady state PK profile measured on Day 10
Time Frame
Day 10 pre-dose, 20 and 40 minutes post-dose, 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose
Title
Number of Participants With Clinically Relevant Treatment-related Changes in Laboratory Variables Other Than Monocytes
Time Frame
up to 47 days (visit 1 to visit 6)
Title
Number of Participants With Clinically Relevant Changes in Vital Signs
Time Frame
up to 47 days (visit 1 to visit 6)
Title
Number of Participants With Clinically Relevant Changes in Electrocardiogram (ECG) Variables
Time Frame
up to 47 days (visit 1 to visit 6)
Title
Number of Participants With Clinically Relevant Changes in Physical Examination
Time Frame
up to 47 days (visit 1 to visit 6)
Title
Number of Participants With Treatment-related or Clinically Relevant Changes in Spirometry (Forced Expiratory Volume in 1 Second [FEV1], Forced Vital Capacity [FVC] Pre-bronchodilator)
Time Frame
up to 47 days (visit 1 to visit 6)
Title
CC16 Concentration in BAL (Post-LPS Challenge)
Description
Post-LPS challenge CC16 concentration in BAL (Day 11). LPS challenge and post-LPS challenge BAL conducted at right middle lobe.
Time Frame
Day 11

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Only women of non-child bearing potential are included in the study i.e. women who are permanently or surgically sterilised or post menopausal. ≥ 40 years of age at Visit 1 Clinical diagnosis of COPD (GOLD stage 1) FEV1 ≥ 80% of the predicted normal post-bronchodilator at Visit 1 (GOLD stage 1) FEV1/FVC <70% post-bronchodilator at Visit 1 (GOLD stage 1) Exclusion Criteria: Any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk or influence the way the drug works Any clinically relevant abnormal findings in physical examination, blood or urine test results, vital signs or ECG at Visit 1 that may put the subject at risk during the study, affect their ability or take part or influence the results of the study A past history or current indication of renal (kidney) failure Subjects at risk of active tuberculosis or of disease reactivation Subjects who have had any clinically significant illness within 4 weeks before Visit 2 (start of treatment)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bengt Larsson
Organizational Affiliation
AstraZeneca R&D
Official's Role
Study Director
Facility Information:
Facility Name
Research Site
City
Hannover
Country
Germany

12. IPD Sharing Statement

Links:
URL
http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=206&filename=CSR-D3320C00001.pdf
Description
D3320C00001 Clinical Study Report Synopsis
URL
http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=206&filename=D3320C00001.pdf
Description
D3320C00001 CSR Synopsis

Learn more about this trial

Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)

We'll reach out to this number within 24 hrs